07:00 , Aug 15, 2016 |  BioCentury  |  Finance

De-risking first in class

Cleave Biosciences Inc. has steered clear of non-dilutive partnership dollars in hopes of internally validating the profile of its first-in-class cancer therapeutic CB-5083. Now, the biotech has attracted a cadre of new investors in last...
07:00 , Aug 8, 2016 |  BC Extra  |  Top Story

Cleave raises $37M in series B

Cleave Biosciences Inc. (Burlingame, Calif.) raised $37 million in a series B round. New investors Celgene Corp. (NASDAQ:CELG), Nextech Invest and Arcus Ventures joined existing investors 5AM Ventures, Clarus, New Enterprise Associates, OrbiMed Advisors, U.S....
07:00 , Sep 15, 2014 |  BC Week In Review  |  Clinical News

CB-5083: Phase I started

Cleave began a 2-stage, open-label, U.S. Phase I trial of oral CB-5083 in up to 60 patients who received >=2 lines of therapy, including an immunomodulatory agent and a proteasome inhibitor, and are ineligible for...